An SST2 agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Seglitide (acetate)

Item No. 42497

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
cyclo(N-methyl-L-alanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-phenylalanyl), acetate
Synonyms
  • Cyclic [N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe]
  • MK-678
Molecular Formula
C44H56N8O7 • XC2H4O2
Formula Weight
809.0
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
cyclo(XYwKVF) (X=N-methylalanine)
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml
SMILES
O=C([C@@H](NC([C@@H](N(C([C@@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)CC2=CC=CC=C2)=O)C)C)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.CC(O)=O
InChi Code
InChI=1S/C44H56N8O7.C2H4O2/c1-26(2)38-43(58)50-37(23-28-12-6-5-7-13-28)44(59)52(4)27(3)39(54)48-35(22-29-17-19-31(53)20-18-29)41(56)49-36(24-30-25-46-33-15-9-8-14-32(30)33)42(57)47-34(40(55)51-38)16-10-11-21-45;1-2(3)4/h5-9,12-15,17-20,25-27,34-38,46,53H,10-11,16,21-24,45H2,1-4H3,(H,47,57)(H,48,54)(H,49,56)(H,50,58)(H,51,55);1H3,(H,3,4)/t27-,34-,35-,36+,37-,38-;/m0./s1
InChi Key
FIKSSPSBVSPVFU-WIKDFEFZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $103

    Add

    5 mg

    $282

    Add

    10 mg

    $461

    Add

    25 mg

    $896

    Add
    Product Description

    Seglitide is an agonist of somatostatin receptor 2 (SST2).1 It inhibits forskolin-induced cAMP accumulation in CCL-39 cells expressing recombinant human SST2 (EC50 = 0.093 nM) but also those expressing recombinant human SST3 or SST5 (EC50s = 209 and 0.47 nM, respectively), of which all are subtypes of the group 1 SST receptor, also known as the somatotropin release inhibiting factor 1 (SRIF1) receptor. However, at higher concentrations, seglitide inhibits somatostatin-14-, somatostatin-25-, or somatostatin-28-induced developed tension in spontaneously beating guinea pig right atria (pA2s = 6.5, 6.24, and 6.09, respectively).2 Seglitide selectively binds to SST2, SST3, and SST5 (Kds = 0.15, 21, and 0.06 nM, respectively, using CGP 23996 as the radioligand) over SST1 and SST4, which comprise the SRIF2 receptor (Kds = 13.5 and 9.1 µM, respectively, using CGP 23996 as the radioligand).3 It inhibits gastrin-, dimaprit-, or IBMX-induced acid secretion in isolated rat gastric mucosa (EC50s = 6, 17, and 13 nM, respectively).4 In vivo, seglitide (500 ng/animal) increases extracellular dopamine levels in the ipsilateral nucleus accumbens in rats when infused into the ventral subiculum.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Siehler, S., and Hoyer, D. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity. Naunyn Schmiedebergs Arch. Pharmacol. 360(5), 510-521 (1999).

    2. Dimech, J., Feniuk, W., and Humphrey, P.P. Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria. Br. J. Pharmacol. 109(4), 898-899 (1993).

    3. Siehler, S., Seuwen, K., and Hoyer, D. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch. Pharmacol. 360(5), 488-499 (1999).

    4. Wyatt, M.A., Jarvie, E., Feniuk, W., et al. Somatostatin sst2 receptor-mediated inhibition of parietal cell function in rat isolated gastric mucosa. Br. J. Pharmacol. 119(5), 905-910 (1996).

    5. Mitchell, S.N., Sharrott, A., Cooper, J., et al. Ventral subiculum administration of the somatostatin receptor agonist MK-678 increases dopamine levels in the nucleus accumbens. Eur. J. Pharmacol. 395(1), 43-46 (2000).